Cinclus Pharma Holding AB (publ) (STO: CINPHA)

Market Cap	944.48M
Revenue (ttm)	n/a
Net Income (ttm)	-157.91M
Shares Out	46.54M
EPS (ttm)	-4.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65,573
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	19.00 - 40.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 20, 2025

About Cinclus Pharma Holding AB

Cinclus Pharma Holding AB (publ), a clinical stage pharmaceutical company, engages in the development of the drug candidate for the treatment of related diseases. Its lead product is linaprazan glurate for the treatment of gastroesophageal reflux disease (GERD) and peptic ulcer bacteria Helicobacter pylori (H. pylori). The company was founded in 2014 and is based in Stockholm, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CINPHA

Financial Performance

In 2023, Cinclus Pharma Holding AB's revenue was 5.96 million, a decrease of -43.63% compared to the previous year's 10.57 million. Losses were -215.12 million, -13.63% less than in 2022.